NCT05578092 2026-02-19A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayMirati Therapeutics Inc.Phase 1 Terminated64 enrolled
NCT06764771 2025-12-17A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsBristol-Myers SquibbPhase 1 Active not recruiting437 enrolled
NCT03785249 2025-09-30Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Mirati Therapeutics Inc.Phase 1/2 Active not recruiting731 enrolled 3 FDA
NCT06039384 2025-08-03A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationIncyte CorporationPhase 1 Terminated6 enrolled
NCT06024174 2025-07-22A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsBristol-Myers SquibbPhase 1/2 Terminated5 enrolled 9 charts
NCT04330664 2025-04-04Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)Mirati Therapeutics Inc.Phase 1 Completed86 enrolled
NCT04975256 2024-12-16Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)Mirati Therapeutics Inc.Phase 1 Terminated7 enrolled